Selumetinib sulfate is also being tested in patients with locally advanced or metastatic pancreatic cancer harboring KRAS G12R mutations (Clinicaltrials.gov Identifier: NCT03040986 (accessed on 24 February 2021)). Here, KRAS is linked to familial pancreatic carcinoma.